- Trials with a EudraCT protocol (323)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
323 result(s) found for: Genetic association.
Displaying page 3 of 17.
EudraCT Number: 2007-005543-22 | Sponsor Protocol Number: TKT028 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire HGT) | |||||||||||||
Full Title: A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease | |||||||||||||
Medical condition: Fabry Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005329-26 | Sponsor Protocol Number: CV027-031 | Start Date*: 2023-01-24 | ||||||||||||||||
Sponsor Name:Myokardia, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | ||||||||||||||||||
Medical condition: Symptomatic Nonobstructive Hypertrophic Cardiomyopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) IT (Prematurely Ended) NL (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-005039-94 | Sponsor Protocol Number: IC2019-05 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Institut Curie | |||||||||||||
Full Title: RETINO 2018 : Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome. | |||||||||||||
Medical condition: Retinoblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003098-24 | Sponsor Protocol Number: CLCZ696I12201 | Start Date*: 2019-12-18 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardio... | |||||||||||||
Medical condition: non-obstructive hypertrophic cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FI (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002598-22 | Sponsor Protocol Number: MK-3475-782 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782) | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003836-77 | Sponsor Protocol Number: OCTO-003 | Start Date*: 2008-12-09 |
Sponsor Name:University of Oxford | ||
Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis. | ||
Medical condition: Barrett's Metaplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007190-20 | Sponsor Protocol Number: D144AC00003 | Start Date*: 2009-12-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) i... | |||||||||||||
Medical condition: Acut mania in subjects with bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010516-15 | Sponsor Protocol Number: 3227K1-2000-WW | Start Date*: 2009-08-14 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Metho... | |||||||||||||
Medical condition: Rheumatoid arthritis (seropositive) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011222-34 | Sponsor Protocol Number: SYR-322_402 | Start Date*: 2009-11-09 | ||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Di... | ||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) HU (Completed) ES (Completed) CZ (Completed) SE (Completed) DE (Completed) FR (Completed) DK (Completed) IT (Completed) BG (Completed) LV (Completed) FI (Completed) LT (Completed) AT (Completed) SK (Completed) PT (Completed) GB (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003647-30 | Sponsor Protocol Number: LAQ-MS-305 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dos... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) LV (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002810-20 | Sponsor Protocol Number: D356FC00003 | Start Date*: 2007-09-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and ... | |||||||||||||
Medical condition: Dyslipidemia - Expert groups have identified low-density lipoprotein cholesterol (LDL-C) as the primary target for cholesterol lowering therapy because it is strongly associated with coronary heart... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020404-29 | Sponsor Protocol Number: H9V-MC-GFRF | Start Date*: 2011-04-08 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited, Indianapolis | |||||||||||||
Full Title: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 D... | |||||||||||||
Medical condition: Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001427-12 | Sponsor Protocol Number: CACZ885M2201 | Start Date*: 2013-06-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and effects on arterial structure and function of ACZ885 in patients with intermittent claudication | |||||||||||||
Medical condition: Peripheral Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002242-17 | Sponsor Protocol Number: B00844 | Start Date*: 2020-07-30 | |||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy. | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy (HCM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002114-40 | Sponsor Protocol Number: APHP200527 | Start Date*: 2020-07-30 |
Sponsor Name:Assistance Publique - Hôpitaux de Paris | ||
Full Title: Nintedanib for the treatment of SARS-Cov-2 induced pulmonary fibrosis | ||
Medical condition: Patients 2 to 6 months after Covid-19 acute pneumonia | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004600-19 | Sponsor Protocol Number: PAINTER01 | Start Date*: 2014-01-21 |
Sponsor Name:Azienda Ospedaliera Fatebenefratelli e Oftalmico - Milano, Italy | ||
Full Title: Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with meta... | ||
Medical condition: Patients with metastatic breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019525-34 | Sponsor Protocol Number: MO22923 | Start Date*: 2010-12-17 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA | |||||||||||||||||||||||
Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004332-79 | Sponsor Protocol Number: GINECO-BR105 | Start Date*: 2007-07-10 |
Sponsor Name:ARCAGY | ||
Full Title: "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sei... | ||
Medical condition: metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001996-35 | Sponsor Protocol Number: GS-US-431-4566 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic ... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) PL (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004275-70 | Sponsor Protocol Number: GPD-01-01 | Start Date*: 2016-01-08 |
Sponsor Name:Gene PreDiT SA | ||
Full Title: Influence of single nucleotide polymorphisms of carboxypeptidase D (CPD) gene on body weight and fat mass reduction by perindopril in obese subjects: A phase II, multicenter, double-blind study. | ||
Medical condition: Body weight and fat mass reduction by perindopril in obese subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
